Yin Y, Rodriguez JL, Li N, et al. Locally Secreted BiTEs Complement CAR T Cells by Enhancing Killing of Antigen Heterogeneous Solid Tumors. Molecular Therapy. 2022; 30 (7): 2537 (doi: 10.1016/j.ymthe.2022.05.011).
Researchers used a glioblastoma model to demonstrate how bispecific T cell engagers (BiTEs) — antibodies that reroute T cells to select antigen-expressing tumors — might prove helpful in the treatment of solid tumors. The key, according to the investigators, is their high sensitivity and specificity. When secreted by mono- or multivalent T cells, BiTEs mediated robust anti-tumor activity in vitro and in vivo. Activation, cytokine production, and cytotoxicity in response to target-positive gliomas all were enhanced with BiTE T cells, relative to chimeric antigen receptor (CAR) T cells. The hyper response was also observed in BiTE-secreting bivalent T cells when compared with bivalent CAR T cells, but the effect was not durable as it was with mono- and multivalent T cells.
Tags: bispecific t cell engagers, patient care, Cellular therapy, BiTEs, antibodies, CART, tumors, T cells, Chimeric antigen receptor, solid tumors